Absci Corporation (ABSI)
NASDAQ: ABSI
· Real-Time Price · USD
3.00
-0.12 (-3.85%)
At close: Aug 14, 2025, 3:59 PM
2.99
-0.33%
Pre-market: Aug 15, 2025, 06:21 AM EDT
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.
Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
| Country | United States |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington United States | |
| Website | https://www.absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 45-3931977 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President & Director |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer & Chief Financial Officer |
| Karin Wierinck | Chief People Officer |
| Shelby Walker J.D. | Chief Legal Officer |
| Alexander Khan CPA | Vice President of Finance & Head of Investor Relations |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer & Member of Scientific Advisory Board |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio & Growth Strategy |
| Melissa Patterson Ph.D. | Chief of Staff |
| Todd Bedrick CPA | Senior Vice President & Chief Accounting Officer |
| Wen Sha | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 8-K/A | [Amend] Current Report |
| Aug 12, 2025 | S-3 | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 29, 2025 | 4 | Filing |
| Jul 25, 2025 | 424B5 | Filing |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 424B5 | Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | [Amend] Filing |